{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:42:17Z","timestamp":1782949337454,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ophtha.2022.09.013","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:01:08Z","timestamp":1663804868000},"page":"167-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Progression of Polypoidal Lesions Associated with Exudative Recurrence in Polypoidal Choroidal Vasculopathy"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9289-2274","authenticated-orcid":false,"given":"Qiyu","family":"Bo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-6517","authenticated-orcid":false,"given":"Jieqiong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1336-1695","authenticated-orcid":false,"given":"Mengxi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9823-702X","authenticated-orcid":false,"given":"Mengsha","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2793-1473","authenticated-orcid":false,"given":"Peirong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-1254","authenticated-orcid":false,"given":"Tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4068-6671","authenticated-orcid":false,"given":"Philip J.","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5015-0945","authenticated-orcid":false,"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2022.09.013_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","article-title":"Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians","volume":"53","author":"Wong","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2022.09.013_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","article-title":"Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup","volume":"128","author":"Cheung","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2022.09.013_bib3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2022.09.013_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ceo.13114","article-title":"Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of 'expanded spectra' - a review","volume":"46","author":"Dansingani","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV)","volume":"10","author":"Yannuzzi","year":"1990","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2022.09.013_bib6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.preteyeres.2013.09.003","article-title":"Photodynamic therapy for polypoidal choroidal vasculopathy","volume":"37","author":"Nowak-Sliwinska","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2022.09.013_bib7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","article-title":"Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results","volume":"156","author":"Oishi","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II Randomized Clinical Trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study","volume":"204","author":"Wong","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/bjophthalmol-2018-311963","article-title":"Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy","volume":"103","author":"Miyata","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jfma.2019.04.012","article-title":"Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan","volume":"119","author":"Chen","year":"2020","journal-title":"J\u00a0Formos Med Assoc"},{"key":"10.1016\/j.ophtha.2022.09.013_bib12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2022.09.013_bib13","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","article-title":"Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW Trials","volume":"123","author":"Waldstein","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2022.09.013_bib14","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/eye.2017.126","article-title":"Submacular hemorrhage and grape-like polyp clusters: factors associated with reactivation of the lesion in polypoidal choroidal vasculopathy","volume":"31","author":"Kim","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2022.09.013_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bjophthalmol-2017-310448","article-title":"Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy","volume":"102","author":"Hikichi","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/IAE.0000000000002035","article-title":"Short-term efficacy of conbercept and ranibizumab for polypoidal choroidal vasculopathy","volume":"39","author":"Huang","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2022.09.013_bib17","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/bjophthalmol-2013-304046","article-title":"Outcomes of polypoidal choroidal vasculopathy treated with ranibizumab monotherapy","volume":"97","author":"Tan","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12886-019-1245-4","article-title":"Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study","volume":"19","author":"Yang","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/bjophthalmol-2018-311963","article-title":"Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy","volume":"103","author":"Miyata","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ajo.2013.05.038","article-title":"Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy","volume":"156","author":"Kang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00417-015-3241-6","article-title":"Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy","volume":"254","author":"Kang","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib22","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/eye.2011.110","article-title":"Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy","volume":"25","author":"Oishi","year":"2011","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2022.09.013_bib23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/bjophthalmol-2012-302652","article-title":"Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy","volume":"97","author":"Hikichi","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib24","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00417-019-04317-y","article-title":"Enlargement of polypoidal choroidal vasculopathy lesion without exudative findings assessed in en face optical coherence tomography images","volume":"257","author":"Kwon","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib25","article-title":"Recurrence and visual prognostic factors of polypoidal choroidal vasculopathy: 5-year results","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ophtha.2022.09.013_bib26","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1097\/IAE.0000000000000499","article-title":"Three-year results of polypoidal choroidal vasculopathy with photodynamic therapy: retrospective study and systematic review","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2022.09.013_bib27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaophthalmol.2019.0449","article-title":"Appearance of polypoidal lesions in patients with polypoidal choroidal vasculopathy using swept-source optical coherence tomographic angiography","volume":"137","author":"Bo","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib28","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaophthalmol.2019.0565","article-title":"Sensitivity and specificity of potential diagnostic features detected using fundus photography, optical coherence tomography, and fluorescein angiography for polypoidal choroidal vasculopathy","volume":"137","author":"Chaikitmongkol","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib29","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1097\/IAE.0000000000002760","article-title":"Diagnostic characteristics of polypoidal choroidal vasculopathy based on b-scan swept-source optical coherence tomography angiography and its interrater agreement compared with indocyanine green angiography","volume":"40","author":"Fujita","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2022.09.013_bib30","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41433-020-01390-0","article-title":"Small dome-shaped pigment epithelium detachment in polypoidal choroidal vasculopathy: an under-recognized sign of polypoidal lesions on optical coherence tomography?","volume":"36","author":"Wang","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2022.09.013_bib31","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2022.09.013_bib32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00417-020-04924-0","article-title":"Clinical characteristics of super stable polypoidal choroidal vasculopathy after initial remission with anti-VEGF monotherapy","volume":"259","author":"Choi","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib33","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00417-015-2933-2","article-title":"The natural history of polypoidal choroidal vasculopathy: a multi-center series of untreated Asian patients","volume":"253","author":"Cheung","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0002-9394(02)01404-6","article-title":"Polypoidal choroidal vasculopathy: natural history","volume":"133","author":"Uyama","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/bjo.2011.204123","article-title":"Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy","volume":"96","author":"Wakabayashi","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2022.09.013_bib36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/iovs.62.6.14","article-title":"Swept-source OCT angiographic characteristics of treatment-naive nonexudative macular neovascularization in AMD prior to exudation","volume":"62","author":"Shen","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2022.09.013_bib37","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1097\/IAE.0000000000001451","article-title":"Recurrence of choroidal neovascularization lesion activity after aflibercept treatment for age-related macular degeneration","volume":"37","author":"Wakazono","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2022.09.013_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.oret.2021.10.006","article-title":"Predicting the onset of exudation in treatment-naive eyes with nonexudative age-related macular degeneration","volume":"6","author":"Shen","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2022.09.013_bib39","article-title":"Replacement of polyps with type 1 macular neovascularization in polypoidal choroidal vasculopathy imaged with swept source OCT angiography","volume":"22","author":"Shen","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.ophtha.2022.09.013_bib40","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.ophtha.2015.06.053","article-title":"Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study","volume":"122","author":"Kuroda","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2022.09.013_bib41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/iovs.62.15.5","article-title":"Choroidal changes in eyes with polypoidal choroidal vasculopathy after anti-VEGF therapy imaged with swept-source OCT angiography","volume":"62","author":"Shen","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642022007485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642022007485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:12:43Z","timestamp":1758982363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642022007485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0161642022007485"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2022.09.013","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progression of Polypoidal Lesions Associated with Exudative Recurrence in Polypoidal Choroidal Vasculopathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2022.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}